Pfizer has discontinued a development program for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy in lung cancer. The program includes two Phase III trials and two Phase II trials. Pfizer licensed the compound from Coley Pharmaceutical Group in 2005. Rights to the drug have reverted to Coley. Interim analysis of the Phase III trials by an independent Data Safety Monitoring Committee (DSMC) showed that PF-3512676 did not produce additional clinical efficac...